Disease-Drug Interactions Requiring Special Attention.

Dongre K; Jungo A; Späni S; Zysset Y; Leuppi-Taegtmeyer A. Praxis. 2022.

High-dose vitamin D substitution in patients with COVID-19: study protocol for a randomized, double-blind, placebo-controlled, multi-center study-VitCov Trial.

Jaun F; Boesing M; Lüthi-Corridori G; Abig K; Makhdoomi A; Bloch N; Lins C; Raess A; Grillmayr V; Haas P; Schuetz P; Gabutti L; Muser J; Leuppi-Taegtmeyer AB; Giezendanner S; Brändle M; Leuppi JD. Trials. 2022.

Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial.

Boesing M; Abig K; Brändle M; Brutsche M; Burri E; Frye BC; Giezendanner S; Grutters JC; Haas P; Heisler J; Jaun F; Leuppi-Taegtmeyer AB; Lüthi-Corridori G; Müller-Quernheim J; Nüesch R; Pohl W; Rassouli F; Leuppi JD. Trials. 2022.

[Cough from a pharmacological point of view].

Späni S; Hübner ST; Leuppi-Taegtmeyer A. Therapeutische Umschau. Revue therapeutique. 2021.

A case of intoxication with tea made from Digitalis purpurea.

Lehmann A; Späni S; Harings-Kaim A; Probst C; Christ A; Leuppi-Taegtmeyer AB. Global cardiology science & practice. 2021.

Antiseizure drugs and risk of developing smoking-related chronic obstructive pulmonary disease or lung cancer: A population-based case-control study.

Leuppi-Taegtmeyer AB; Reinau D; Yilmaz S; Rüegg S; Krähenbühl S; Jick SS; Leuppi JD; Meier CR. British journal of clinical pharmacology. 2021.

Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre.

Istampoulouoglou I; Zimmermanns B; Grandinetti T; Marzolini C; Harings-Kaim A; Koechlin-Lemke S; Scholz I; Bassetti S; Leuppi-Taegtmeyer AB. Global cardiology science & practice. 2021.

Comparative Effects of Metamizole (Dipyrone) and Naproxen on Renal Function and Prostacyclin Synthesis in Salt-Depleted Healthy Subjects - A Randomized Controlled Parallel Group Study.

Blaser LS; Duthaler U; Bouitbir J; Leuppi-Taegtmeyer AB; Liakoni E; Dolf R; Mayr M; Drewe J; Krähenbühl S; Haschke M. Frontiers in pharmacology. 2021.

Development and Implementation of an e-Trigger Tool for Adverse Drug Events in a Swiss University Hospital.

El Saghir A; Dimitriou G; Scholer M; Istampoulouoglou I; Heinrich P; Baumgartl K; Schwendimann R; Bassetti S; Leuppi-Taegtmeyer A. Drug, healthcare and patient safety. 2021.

Immune thrombocytopenia associated with COVID-19 mRNA vaccine tozinameran - a clinical case and global pharmacovigilance data.

Battegay R; Istampoulouoglou I; Holbro A; Buser A; Hirsiger JR; Eckstein J; Berger CT; Koechlin S; Leuppi-Taegtmeyer AB. Swiss medical weekly. 2021.

Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature.

Hollinger A; Cueni N; Marzolini C; Dickenmann M; Landmann E; Battegay M; Martinez AE; Siegemund M; Leuppi-Taegtmeyer A. AIDS Research and Therapy. 2021.

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre.

Istampoulouoglou I; Dimitriou G; Späni S; Christ A; Zimmermanns B; Koechlin S; Stoeckmann O; Winterhalder C; Marono D; Toma V; Leuppi-Taegtmeyer AB. Global cardiology science & practice. 2021.

Prediction of Acute COPD Exacerbation in the Swiss Multicenter COPD Cohort Study (TOPDOCS) by Clinical Parameters, Medication Use, and Immunological Biomarkers

Huebner S.T.; Henny S.; Giezendanner S.; Brack T.; Brutsche M.; Chhajed P.; Clarenbach C.; Dieterle T.; Egli A.; Frey M.; Heijnen I.; Irani S.; Sievi N.A.; Thurnheer R.; Trendelenburg M.; Kohler M.; Leuppi-Taegtmeyer A.B.; Leuppi J.D.. Respiration; international review of thoracic diseases. 2021.

Prevalence of untreated and uncontrolled cardiovascular risk factors in survivors of allogeneic cell transplantation.

Arranto CA; Burkard T; Leuppi-Taegtmeyer AB; Gerull S; Passweg JR; Pfister O; Halter JP. Bone marrow transplantation. 2021.

Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.

Marzolini C; Stader F; Leuppi-Taegtmeyer A; Stoeckle M; Battegay M; Sendi P. . 2021.

Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland.

Tschacher A; Cadus C; Schildge S; Diedrich JP; Chhajed PN; Leuppi-Taegtmeyer AB; Leuppi JD. Current medical research and opinion. 2021.

The statistical risk of diagnosing coincidental acquired hemophilia A following anti-SARS-CoV-2 vaccination.

Cittone MG; Battegay R; Condoluci A; Terzi di Bergamo L; Fernandes E; Galfetti E; Noseda R; Leuppi-Taegtmeyer A; Drexler B; Ceschi A; Tsakiris DA; Berger CT; Favre G; Martin T; Korte W; Graf L; Martinez M; Gerber B. . 2021.

[Opioid Agonist Therapy (OAT) for opioid dependency].

Köck P; Strasser J. Therapeutische Umschau. Revue therapeutique. 2020.

[Opioids in patients with renal impairment].

Pfefferkorn F; Harings-Kaim A; Schönenberger M; Leuppi-Taegtmeyer A. Therapeutische Umschau. Revue therapeutique. 2020.

Development of a patient-reported outcome questionnaire for aplastic anemia and paroxysmal nocturnal hemoglobinuria (PRO-AA/PNH).

Weisshaar K; Ewald H; Halter J; Gerull S; Schönfeld S; Senft Y; Martinez M; Leuppi-Taegtmeyer A; Khanna N; Maier B; Risitano A; Peffault de Latour R; Tichelli A; Passweg J; Drexler B. Orphanet Journal of Rare Diseases. 2020.

Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.

Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K. . 2020.

High Incidence of New-Onset Joint Pain in Patients on Fluoroquinolones as Antituberculous Treatment.

Mandovra NP; Lele TT; Vaidya PJ; Chavhan VB; Leuppi-Taegtmeyer AB; Leuppi JD; Chhajed PN. Respiration; international review of thoracic diseases. 2020.

Intensive Hemodiafiltration Successfully Removes Ganciclovir Overdose and Largely Exceeds Reported Elimination During Hemodialysis-A Case Report and Review of the Literature.

Gotta V; Leuppi-Taegtmeyer A; Gessler M; Pfister M; Müller D; Jehle AW. Frontiers in pharmacology. 2020.

[Fatal Outcome of Agranulocytosis after Re-Exposure to Metamizole and Cefepime-Induced Encephalopathy].

Skaistys A; Rätz Bravo AE; Leuppi-Taegtmeyer A; Zysset Y. Praxis. 2019.

Danger of Herbal Tea: A Case of Acute Cholestatic Hepatitis Due to Artemisia annua Tea.

Ruperti-Repilado FJ; Haefliger S; Rehm S; Zweier M; Rentsch KM; Blum J; Jetter A; Heim M; Leuppi-Taegtmeyer A; Terracciano L; Bernsmeier C. Frontiers in Medicine. 2019.

Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial

Gregoriano C.; Dieterle T.; Breitenstein A.-L.; Durr S.; Baum A.; Giezendanner S.; Maier S.; Leuppi-Taegtmeyer A.; Arnet I.; Hersberger K.E.; Leuppi J.D.. RESPIRATORY RESEARCH. 2019.

Febrile illness and bicytopenia within hours after tick-borne encephalitis booster vaccination.

Bühler T; Boos N; Leuppi-Taegtmeyer AB; Berger CT. npj Vaccines. 2019.

Hepatotoxicity Due to Azole Antimycotic Agents in a HLA B*35:02-Positive Patient.

Bühler T; Medinger M; Bouitbir J; Krähenbühl S; Leuppi-Taegtmeyer A. Frontiers in pharmacology. 2019.

Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports.

Brockhaus L; Schmid Y; Rast AC; Rätz Bravo AE; Hofmeier KS; Leuppi-Taegtmeyer AB. BMC pharmacology & toxicology. 2019.

Multicenter Population Pharmacokinetic Study of Colistimethate Sodium and Colistin Dosed as in Normal Renal Function in Patients on Continuous Renal Replacement Therapy.

Leuppi-Taegtmeyer AB; Decosterd L; Osthoff M; Mueller NJ; Buclin T; Corti N. Antimicrobial Agents and Chemotherapy. 2019.

Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.

Leuppi-Taegtmeyer A; Duthaler U; Hammann F; Schmid Y; Dickenmann M; Amico P; Jehle AW; Kalbermatter S; Lenherr C; Meyer Zu Schwabedissen HE; Haschke M; Liechti ME; Krähenbühl S. Nephrology Dialysis Transplantation. 2019.

Prevalence of high-risk drug-drug interactions in paediatric inpatients: a retrospective, single-centre cohort analysis.

Dieu LW; Leuppi-Taegtmeyer AB; van den Anker J; Trachsel D; Gotta V. Swiss medical weekly. 2019.

C-Reactive Protein and Procalcitonin in Case Reports of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Hübner ST; Bertoli R; Rätz Bravo AE; Schaueblin M; Haschke M; Scherer K; Ceschi A; Leuppi-Taegtmeyer AB. International archives of allergy and immunology. 2018.

Dyslipidemia and lipid-lowering treatment in a hematopoietic stem cell transplant cohort: 25 years of follow-up data.

Premstaller M; Perren M; Koçack K; Arranto C; Favre G; Lohri A; Gerull S; Passweg JR; Halter JP; Leuppi-Taegtmeyer AB. Journal of Clinical Lipidology. 2018.

Leucopenia associated with metamizole: a case-control study.

Blaser L; Hassna H; Hofmann S; Holbro A; Haschke M; Rätz Bravo A; Zeller A; Krähenbühl S; Taegtmeyer A. Swiss medical weekly. 2017.

Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity.

Hammann F; Gotta V; Conen K; Medinger M; Cesana P; Rochlitz C; Taegtmeyer AB. British journal of clinical pharmacology. 2017.

Torsade de pointes and systemic azole antifungal agents: Analysis of global spontaneous safety reports.

Salem M; Reichlin T; Fasel D; Leuppi-Taegtmeyer A. Global cardiology science & practice. 2017.

Breakthrough Pain Associated with a Reduction in Serum Buprenorphine Concentration during Dialysis.

Salili AR; Müller D; Skendaj R; Jehle AW; Taegtmeyer AB. CLINICAL THERAPEUTICS. 2016.

Response to Letter From Ruan and Bumgarner: Breakthrough Pain Associated With a Reduction in Serum Buprenorphine Concentration During Dialysis.

Salili AR; Müller D; Skendaj R; Jehle AW; Taegtmeyer AB. CLINICAL THERAPEUTICS. 2016.

Severe taxane skin reaction due to a drug interaction with amiodarone: a case report

Hammann, Felix; Conen, Katrin; Medinger, Michael; Cesana, Philipp; Rochlitz, Christoph; Taegtmeyer, Anne B.. Clinical toxicology (Philadelphia, Pa.). 2016.

[Fatal agranulocytosis after metamizole reexposure].

Zeiner E; Blaser LS; Tisljar K; Heim D; Taegtmeyer A. Praxis. 2015.

Acute mycophenolate overdose: case series and systematic literature analysis.

Ceschi A; Gregoriano C; Rauber-Lüthy C; Kupferschmidt H; Banner NR; Krähenbühl S; Taegtmeyer AB. Expert opinion on drug safety. 2014.

Acute thiopurine overdose: analysis of reports to a National Poison Centre 1995-2013.

Gregoriano C; Ceschi A; Rauber-Lüthy C; Kupferschmidt H; Banner NR; Krähenbühl S; Taegtmeyer AB. PLoS One. 2014.

AMP deaminase 1 gene polymorphism and heart disease-a genetic association that highlights new treatment.

Smolenski RT; Rybakowska I; Turyn J; Romaszko P; Zabielska M; Taegtmeyer A; Słomińska EM; Kaletha KK; Barton PJ. Cardiovascular Drugs and Therapy. 2014.

An open-label study examining the effect of pharmacological treatment on mannitol- and exercise-induced airway hyperresponsiveness in asthmatic children and adolescents with exercise-induced bronchoconstriction.

Schafroth Török S; Mueller T; Miedinger D; Jochmann A; Zellweger LJ; Sauter S; Goll A; Chhajed PN; Taegtmeyer AB; Knöpfli B; Leuppi JD. BMC Pediatrics. 2014.

A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls.

Taegtmeyer AB; Haschke M; Tchambaz L; Buylaert M; Tschöpl M; Beuers U; Drewe J; Krähenbühl S. PLoS One. 2014.

Bronchial hyperresponsiveness testing in athletes of the Swiss Paralympic team.

Osthoff M; Michel F; Strupler M; Miedinger D; Taegtmeyer AB; Leuppi JD; Perret C. BMC sports science, medicine & rehabilitation. 2013.

Multifocal CNS demyelination after octreotide treatment for metastatic meningioma.

Schreglmann SR; Jelčić I; Taegtmeyer AB; Linnebank M; Weller M. Clinical neurology and neurosurgery. 2013.

[Clinically important food-drug interactions: what the practitioner needs to know].

Corti N; Taegtmeyer AB. Praxis. 2012.

[Interaction of drugs with the primary disease - when medicines exacerbate illnesses].

Taegtmeyer A; Curkovic I; Corti N. Praxis. 2012.

Clinical usefulness of electronic drug-drug interaction checking in the care of cardiovascular surgery inpatients.

Taegtmeyer AB; Kullak-Ublick GA; Widmer N; Falk V; Jetter A. Cardiology. 2012.

Drug-related problems and factors influencing acceptance of clinical pharmacologists' alerts in a large cohort of neurology inpatients

Taegtmeyer, Anne B.; Curkovic, Ivanka; Corti, Natascia; Rosen, Christoph; Egbring, Marco; Russmann, Stefan; Gantenbein, Andreas R.; Weller, Michael; Kullak-Ublick, Gerd A.. Swiss Medical Weekly. 2012.

Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol.

Scherr A; Schafroth Török S; Jochmann A; Miedinger D; Maier S; Taegtmeyer AB; Chhajed PN; Tamm M; Leuppi JD. Chest. 2012.

Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.

Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA. Swiss medical weekly. 2012.